This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Usted está a punto de salir de la página web de GSK

Este enlace lo llevará a un sitio web que no pertenece a GSK. GSK no recomienda, aprueba ni acepta responsabilidad por los sitios controlados por terceros.

Continuar

Regresar

60 results

Triumeq

Dolutegravir-Abacavir-Lamivudina<br> VIH

Índice terapéutico

A video explanation of therapeutic index and how Relvar’s good therapeutic index is linked to the high receptor binding affinity of its constituent molecules.

Casualidad o elección

Casualidad o elección

Dispositivo

Dispositivo

Seguridad

Seguridad

Monitoreo de la dependencia de SABA

GINA guidelines state that SABA use > twice weekly suggests poor asthma control. Real-world data vs budesonide/formoterol show how Relvar reduces SABA dependence.

EL SLS

Relvar efficacy data from the SLS, which included patients with comorbidities and those who were smokers, who would usually be excluded from RCTs.

Efectos en el cortisol y el eje HHS

The maximum licensed dose of Relvar does not affect the HPA axis or significantly suppress cortisol levels.

Adherencia

Real-world data showing that Relvar new users were more adherent to, and less likely to discontinue, treatment than new users of other ICS/LABA combinations.

Impacto Ambiental

Published data showing that Relvar has a lower annual carbon footprint and lower lifecycle contributions than many other asthma devices.

Tamaño de la partícula

Relvar’s particle size falls well within the optimal range for absorption, a factor in asthma control that is often overlooked.

Generalidades

Key Relvar benefits in adults/adolescents with uncontrolled, partially controlled or adequately controlled asthma.

Celsentri

Maraviroc <br> VIH

Combivir

Lamivudina-Zidovudina<br> VIH

Apretude

Cabotegravir/Cabotegravir sódico <br> VIH

Percepción de los pacientes vs. la realidad

Patient case studies showing how patient perceptions of asthma control differ from guideline definitions.

Alcanzando el control del asma

How Relvar can achieve asthma control, using guideline definitions and ACT assessment (includes an external link to the ACT website).

Decodificando Relvar

Relvar Ellipta’s ease of use is shown by a video and by data vs Breezehaler, while its preference by patients vs Turbohaler, Diskus, and MDI is highlighted.

Meeting in a Box: Estudio APPaRENT

Meeting in a Box: Estudio APPaRENT

Exacerbaciones

Real-world evidence and clinical trial data reveal how Relvar can reduce the rate of asthma exacerbations vs budesonide/formoterol and ICS, respectively.

Calidad de vida

Post-hoc analysis night-time awakening data from three RCTs and AQLQ data showing how patients with uncontrolled asthma can benefit from taking Relvar.

Cambiando a Relvar

A patient case study illustrates how Relvar can address invisible symptoms vs patient perceptions of asthma control with ICS/LABA MART regimens.

Control duradero

Data showing that Relvar’s unique formulation provides continuous improvements in lung function and anti-inflammatory effects over the 24-h dosing interval.

Dispositivo

Relvar Ellipta’s ease of use is shown by a video and by data vs Breezehaler, while its preference by patients vs Turbohaler, Diskus, and MDI is highlighted.

Perfiles de pacientes

Perfiles de pacientes

HZ e inmunoscenensencia

HZ e inmunoscenensencia

SHINGRIX en su práctica

SHINGRIX en su práctica

Seguridad

Seguridad

Consejería de pacientes

Caso Interactivo

Recomendación

Recomendación

Centro de vídeos

Centro de vídeos

Eficacia

Eficacia

NPH y eficacia sostenida

NPH y eficacia sostenida

Consejería de pacientes

Grupo de contacto

Esquemas de vacunación

Esquemas de vacunación

≥ 18 años con riesgo incrementado de padecer HZ

≥ 18 años con riesgo incrementado de padecer HZ

Fundamento científico

Fundamento científico

Seretide en Pediatría

Seretide en Pediatría

Seguridad

Seguridad

Inicio

Inicio

Guías

amoxicillin-clavulanate<br>Anti infectives

Eficacia

amoxicillin-clavulanate<br>Anti infectives

Intercambiabilidad

amoxicillin-clavulanate<br>Anti infectives

Novedades

amoxicillin-clavulanate<br>Anti infectives

Inicio

amoxicillin-clavulanate<br>Anti infectives

Susceptibilidad

amoxicillin-clavulanate<br>Anti infectives

Recursos

Recursos

No hubo coincidencias. Intente por favor:

  • Revisar la ortografía del término de búsqueda.
  • Intente un nuevo término de búsqueda.
  • Reestablecer o revisar los filtros de búsqueda (si utilizó filtros para esta búsqueda)

Mostrar más